詳細(xì)介紹
Her2(細(xì)胞表面生長因子受體2)
廣州健侖生物科技有限公司
C-erbB-2 癌基因又稱neu或HER-2,它編碼一種具有酪氨酸激酶活性的跨膜糖蛋白,又稱p185蛋白。C-erbB-2屬于酪氨酸激酶(RTK)家族中的生長因子受體C-erbB亞家族。在差不多40%的乳腺癌病人中可以檢測到 C-erbB-2 的過表達(dá)。C-Cbl與C-erbB-2的Tyr1112結(jié)合后,形成了多聚 C-erbB-2,從而加速了C-erbB-2 的降解。C-erbB-2基因是治療乳腺癌等腫瘤的主要靶點(diǎn)之一。 該基因表達(dá)還可作為判斷乳腺癌、卵巢癌、子宮內(nèi)膜癌及消化道腫瘤預(yù)后的參考指標(biāo)。
總的來講,本文的研究發(fā)現(xiàn)為開發(fā)一種新型模型,來揭示Sall4如何被招募回DNA的破碎位點(diǎn)從而激活一種名為ATM的激酶提供了新的希望,ATM是一種特殊激酶,其可以發(fā)送DNA損傷的信號從而誘導(dǎo)修復(fù)過程,由于腫瘤細(xì)胞通常都會發(fā)生Sall4過表達(dá)的情況,因此這種蛋白或許就可以幫助腫瘤細(xì)胞修復(fù)DNA損傷,因此研究人員認(rèn)為Sall4或許是未來開發(fā)新型癌癥療法的一種新型靶點(diǎn)。
近日,一篇發(fā)表于雜志EMBO molecular Medicine上的研究報告中,來自洛桑大學(xué)醫(yī)院(Lausanne University Hospital)的研究人員通過研究設(shè)計了一種新型策略,其可以幫助確保成人表皮干細(xì)胞在應(yīng)用于病人療法之前是安全的;這種新型方法包括了一種克隆策略,其可以使得干細(xì)胞在進(jìn)行檢測以達(dá)到zui高安全標(biāo)準(zhǔn)之前被大量收集并且進(jìn)行培養(yǎng),隨后進(jìn)行遺傳化修飾以及單個細(xì)胞的分離。
研究者Yann Barrandon表示,截至目前為止并沒有一種系統(tǒng)性的方法來確保成人表皮干細(xì)胞在進(jìn)行疾病治療前可以滿足所必需的安全性要求,而本文研究中我們發(fā)明了一種單細(xì)胞技術(shù),其可以在干細(xì)胞用于病人治療之前利用細(xì)胞和分子分析來評估干細(xì)胞的安全性和活力,目前研究者已經(jīng)在一系列臨床療法中對其開發(fā)的新技術(shù)進(jìn)行了概念性的驗證。
文章中研究人員對來自病人機(jī)體的表皮細(xì)胞進(jìn)行培養(yǎng)并且將其用于皮膚再生,而研究者同時也進(jìn)行了一系列實(shí)驗來確定這種轉(zhuǎn)導(dǎo)細(xì)胞是否可以滿足干細(xì)胞多能性及安全性的必須要求;克隆分析結(jié)果顯示,這種轉(zhuǎn)導(dǎo)干細(xì)胞的能力可以發(fā)生改變來產(chǎn)生功能類型的VII膠原,當(dāng)其活力時,修飾的干細(xì)胞就可以被選擇移植進(jìn)入免疫缺陷癥的小鼠機(jī)體中幫助治療疾病,而其安全性則需要通過確定病毒載體的整合位點(diǎn)來決定,其可以通過尋找基因重排來實(shí)現(xiàn),就好比全基因組測序一樣。
zui后研究者表示,我們的研究結(jié)果顯示,至少對于成人表皮干細(xì)胞而言我們可以采用一種克隆的方法來達(dá)到安全級別的運(yùn)輸,而這種克隆策略也可以同其它當(dāng)前的靶向基因組編輯技術(shù)進(jìn)行整合來提供更多的精確技術(shù)幫助提高干細(xì)胞的安全性檢測,以使得干細(xì)胞可以更安全有效地應(yīng)用于臨床疾病的治療中。
初中生物課本中已經(jīng)介紹了細(xì)胞內(nèi)幾種常見的細(xì)胞器:線粒體,高爾基體,內(nèi)質(zhì)網(wǎng),溶酶體,植物中的葉綠體與液泡,中心體,等等。zui近清華大學(xué)俞立課題組在《cell reserch》在線發(fā)表了他們新發(fā)現(xiàn)的一類細(xì)胞亞結(jié)構(gòu)單位:遷移小體(migrasome)。
我司還提供其它進(jìn)口或國產(chǎn)試劑盒:登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。
歡迎咨詢
歡迎咨詢
Her2(細(xì)胞表面生長因子受體2)
【產(chǎn)品介紹】
細(xì)胞定位:細(xì)胞膜
克隆號:EP3
同型:IgG
適用組織:石蠟/冰凍
陽性對照:乳腺癌
抗原修復(fù):熱修復(fù)(EDTA)
抗體孵育時間:30-60min
產(chǎn)品編號 | 抗體名稱 | 克隆型別 |
OB124 | GSTπ(胎盤型谷胱甘肽-S-轉(zhuǎn)移酶) | LW29 |
OB125 | HbcAg(乙肝核心抗原) | polyclonal |
OB126 | HbsAg(乙肝表面抗原) | S1-210 |
OB127 | hCG(絨毛膜促性腺激素) | polyclonal |
OB128 | Helicobacter pylori(幽門螺旋桿菌) | polyclonal |
OB129 | Hemoglobin A(血紅蛋白 A) | EPR3608 |
OB130 | hENT1 (人平衡型核苷轉(zhuǎn)運(yùn)蛋白1) | SP120 |
OB131 | Her2(細(xì)胞表面生長因子受體2) | EP3 |
OB132 | Her2(細(xì)胞表面生長因子受體2) | SP3 |
OB133 | HLA-Dra(人類白細(xì)胞抗原2) | LN-3 |
OB134 | HPV(人乳頭狀瘤病毒) | K1H8 |
OB135 | HSA(肝細(xì)胞特異性抗原)或Hepatocyte Specific Antigen或Hep Par-1 | OCH1E5 |
OB136 | IgA(免疫球蛋白A) | polyclonal |
OB137 | IgD(免疫球蛋白D) | polyclonal |
OB138 | IgG(免疫球蛋白G) | polyclonal |
OB139 | IgG4(免疫球蛋白G4) | MRQ-44 |
OB140 | IgM(免疫球蛋白M) | polyclonal |
Her2(細(xì)胞表面生長因子受體2)
想了解更多的產(chǎn)品及服務(wù)請掃描下方二維碼:
【公司名稱】 廣州健侖生物科技有限公司
【市場部】 歐
【】
【騰訊 】
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室
In summary, the present study provides new hope for the development of a new model to reveal how Sall4 is recruited back to the DNA disruption site to activate a kinase called ATM, a specialized kinase, It can send signals of DNA damage to induce repair. Since Sall4 overexpression usually occurs in tumor cells, this protein may help tumor cells repair DNA damage. Therefore, researchers believe Sall4 may be the future development of new cancer therapies A new target.
In a recent study published in the international journal EMBO molecular Medicine, researchers from Lausanne University Hospital designed a new strategy that could help ensure that adult epidermal stem cells are used in patient therapy Was previously safe; this new approach includes a cloning strategy that allows stem cells to be collected and cultured in large quantities prior to testing to reach the highest safety standards, followed by genetic modification and isolation of individual cells.
Researchers Yann Barrandon said there is no systematic way to ensure that adult epidermal stem cells meet the safety requirements necessary to treat the disease until now, and in the current study we invented a single-cell technique that Cell and molecular analysis can be used to assess the safety and viability of stem cells before stem cells are used in patient care. Researchers have now conceptually validated the new technologies they developed in a range of clinical therapies.
In the article, researchers cultured epidermal cells from the patient's body and used them for skin regeneration. Researchers also conducted a series of experiments to determine whether this kind of transduced cells could meet the pluripotency and safety of stem cells. Requirements; Clonal analysis showed that this ability to transduce stem cells can be altered to produce functional collagen type VII, which when modified is most likely to be selected for transplantation into the immunodeficiency mouse body Treatment of the disease, while its safety needs to be determined by determining the site of integration of the viral vector, can be achieved by looking for gene rearrangements, much like genome-wide sequencing.
The researchers concluded that our results show that at least for adult epidermal stem cells we can use a clonal approach to transport at a safe level and that this cloning strategy can also be used with other current targeted genomic editing techniques Integration to provide more precise techniques to help improve safety testing of stem cells to enable stem cells to be more safely and effectively applied to the treatment of clinical conditions.
Junior high school biology textbook has introduced several common intracellular organelles: mitochondria, Golgi, endoplasmic reticulum, lysosomes, chloroplasts and vacuoles in plants, centrosomes, and so on. Recently, Yu Li, Tsinghua University research group published a new class of cell sub-structure units: migrasome online at "cell reserch."